<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Dysferlin is a transmembrane protein implicated in surface membrane repair of muscle cells </plain></SENT>
<SENT sid="1" pm="."><plain>Mutations in dysferlin cause the progressive <z:hpo ids='HP_0003560'>muscular dystrophies</z:hpo> Miyoshi <z:hpo ids='HP_0003198'>myopathy</z:hpo>, <z:hpo ids='HP_0006785'>limb girdle muscular dystrophy</z:hpo> 2B, and distal anterior compartment <z:hpo ids='HP_0003198'>myopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Dysferlinopathies are inherited in an <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo> manner, and many patients with this disease harbor <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e>-sense mutations in at least one of their two pathogenic DYSF alleles </plain></SENT>
<SENT sid="3" pm="."><plain>These patients have significantly reduced or absent dysferlin levels in skeletal muscle, suggesting that dysferlin encoded by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e>-sense alleles is rapidly degraded by the cellular quality control system </plain></SENT>
<SENT sid="4" pm="."><plain>We reasoned that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e>-sense mutated dysferlin, if salvaged from degradation, might be biologically functional </plain></SENT>
<SENT sid="5" pm="."><plain>We used a dysferlin-deficient human myoblast culture harboring the common R555W <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e>-sense allele and a DYSF-null allele, as well as control human myoblast cultures harboring either two <z:mp ids='MP_0002169'>wild-type</z:mp> or two null alleles </plain></SENT>
<SENT sid="6" pm="."><plain>We measured dysferlin protein and <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels, resealing kinetics of laser-induced plasmalemmal wounds, myotube formation, and cellular viability after treatment of the human myoblast cultures with the <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi> <z:chebi fb="0" ids="52722">lactacystin</z:chebi> or <z:chebi fb="0" ids="52717">bortezomib</z:chebi> (<z:chebi fb="0" ids="52717">Velcade</z:chebi>) </plain></SENT>
<SENT sid="7" pm="."><plain>We show that endogenous R555W <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e>-sense mutated dysferlin is degraded by the proteasomal system </plain></SENT>
<SENT sid="8" pm="."><plain>Inhibition of the proteasome by <z:chebi fb="0" ids="52722">lactacystin</z:chebi> or <z:chebi fb="0" ids="52717">Velcade</z:chebi> increases the levels of R555W <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e>-sense mutated dysferlin </plain></SENT>
<SENT sid="9" pm="."><plain>This salvaged protein is functional as it restores plasma membrane resealing in patient-derived myoblasts and reverses their deficit in myotube formation </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi> and <z:chebi fb="0" ids="52722">lactacystin</z:chebi> did not cause cellular toxicity at the regimen used </plain></SENT>
<SENT sid="11" pm="."><plain>Our results raise the possibility that inhibition of the degradation pathway of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e>-sense mutated dysferlin could be used as a therapeutic strategy for patients harboring certain dysferlin <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">mis</z:e>-sense mutations </plain></SENT>
</text></document>